Minerva Biotechnologies Overview
- Year Founded
-
1999
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.51M
- Investors
-
3
Minerva Biotechnologies General Information
Description
Developer of immunotherapies and drugs designed to target solid tumors and prevent cancer metastasis. The company's drugs generate human naïve state-induced pluripotent stem cells that target the MUC1 growth factor receptor, enabling researchers to design simple colorimetric assays to detect a broad array of antibody-antigen, protein-protein, and protein-ligand interactions.
Contact Information
Website
www.minervabio.comCorporate Office
- 68 Cummings Park
- Woburn, MA 01801
- United States
Corporate Office
- 68 Cummings Park
- Woburn, MA 01801
- United States
Minerva Biotechnologies Timeline
Minerva Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 05-Dec-2023 | $4.51M | Completed | Clinical Trials - Phase 1 | ||
| 9. Later Stage VC | 04-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC | 30-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 02-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 24-Oct-2014 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 10-Jun-2014 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 16-Nov-2010 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | Completed | Clinical Trials - Phase 1 | ||||
| 2. Angel (individual) | 22-Nov-2006 | $478K | $478K | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 01-Jan-2004 | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Minerva Biotechnologies Patents
Minerva Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026206772-A1 | Compositions and methods for the treatment of muc1* positive heterogeneous cancers | Pending | 24-Mar-2025 | ||
| WO-2026050183-A1 | Bacterial nme7 orthologs and uses thereof | Pending | 27-Aug-2024 | ||
| AU-2024357558-A1 | Anti-muc1* antibody drug complexes and uses thereof | Pending | 11-Oct-2023 | ||
| EP-4587063-A1 | Anti-muc1* antibody drug complexes and uses thereof | Pending | 11-Oct-2023 | ||
| US-20250121088-A1 | Anti-muc1* antibody drug complexes and uses thereof | Inactive | 11-Oct-2023 | A61K47/6851 |
Minerva Biotechnologies Signals
Minerva Biotechnologies Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute Of Allergy and Infectious Diseases | Government | |||
| Angel (individual) | Minority | |||
| Springboard Enterprises | Accelerator/Incubator |
Minerva Biotechnologies FAQs
-
When was Minerva Biotechnologies founded?
Minerva Biotechnologies was founded in 1999.
-
Where is Minerva Biotechnologies headquartered?
Minerva Biotechnologies is headquartered in Woburn, MA.
-
What is the size of Minerva Biotechnologies?
Minerva Biotechnologies has 17 total employees.
-
What industry is Minerva Biotechnologies in?
Minerva Biotechnologies’s primary industry is Drug Discovery.
-
Is Minerva Biotechnologies a private or public company?
Minerva Biotechnologies is a Private company.
-
What is Minerva Biotechnologies’s current revenue?
The current revenue for Minerva Biotechnologies is .
-
How much funding has Minerva Biotechnologies raised over time?
Minerva Biotechnologies has raised $60.2M.
-
Who are Minerva Biotechnologies’s investors?
National Institute Of Allergy and Infectious Diseases, , and Springboard Enterprises have invested in Minerva Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process